New! Sign up for our free email newsletter.
Science News
from research organizations

Disarming the immune system's lethal lung response

Date:
September 23, 2022
Source:
Cold Spring Harbor Laboratory
Summary:
Neutrophils are the body's first line of defense against infection. But if too many attack for too long, they can damage the tissues they're meant to protect. In the lungs, this damage can lead to acute respiratory distress syndrome, the leading cause of death due to COVID-19. Researchers have found that using a drug to inhibit a protein called PTP1B can prevent lethal lung inflammation in mice. This discovery may lead to better treatments for severe inflammatory conditions like sepsis and COVID-19.
Share:
FULL STORY

Neutrophils, the most abundant type of white blood cell, are the body's first line of defense against infection. Foreign pathogens can stress the body and activate neutrophils. When activated, neutrophils employ various weapons to protect the body. But if overactivated, these weapons can damage the body's own tissues. Lung tissue is saturated with blood vessels, making them very susceptible to neutrophil attacks. If severe enough, acute lung injuries can lead to acute respiratory distress syndrome (ARDS), the leading cause of death due to COVID-19.

Nicholas Tonks, Caryl Boies professor of cancer research at Cold Spring Harbor Laboratory (CSHL), and his team have found a drug candidate that can prevent lethal lung inflammation in mice by inhibiting a protein called PTP1B. Their discovery may help develop better treatments for severe inflammatory conditions like sepsis and COVID-19.

"When you think about COVID-19, acute lung injury and ARDS underlie the fatal aspects of the disease," Tonks says. "And so, when the pandemic took hold, we were wondering whether there was anything we could do to help, to provide an understanding of this aspect of the disease and suggest ways it could be treated."

Tonks' graduate student Dongyan Song investigated whether using a PTP1B inhibitor drug candidate could dampen the lethal consequences of overactive neutrophils in mice. She found that pretreating mice with the PTP1B inhibitor reduced lung tissue damage. When untreated, less than half of the mice survived acute lung injuries and ARDS. But when pretreated, they all survived.

The researchers exploited a natural process, called neutrophil aging, that the body uses to control the immune cell's lifespan. As they age, neutrophils become less dangerous. Tonks' team discovered PTP1B inhibition speeds up neutrophil aging. "An aged neutrophil is like a soldier without a weapon," Song explains. "So regardless of how many neutrophils flood an area, they won't be able to do serious damage."

This project was part of a program of COVID-related research at CSHL. Tonks says collaborations with CSHL Professor Mikala Egeblad, postdoc Jose M. Adrover, and CSHL Research Associate Professor Scott Lyons were essential to this discovery. Going forward, he and Song are working to increase the understanding of how PTP1B inhibitors affect the immune system. Tonks hopes his lab's continued research leads to new treatments and preventative measures for various inflammatory diseases. His lab is currently working with DepYmed, Inc. to take PTP1B inhibitor drug candidates into clinical trials.

Tonks' lab studies signal transduction, the process that controls how cells respond to signals from their environment. In particular, they focus on the PTP protein family, which Tonks discovered over 30 years ago. Since then, he's sought to develop small molecule drug candidates that target these proteins, which can provide new approaches for treating major human diseases including cancer and metabolic and neurodegenerative diseases.


Story Source:

Materials provided by Cold Spring Harbor Laboratory. Original written by Nick Wurm. Note: Content may be edited for style and length.


Journal Reference:

  1. Dongyan Song, Jose M. Adrover, Christy Felice, Lisa N. Christensen, Xue-Yan He, Joseph R. Merrill, John E. Wilkinson, Tobias Janowitz, Scott K. Lyons, Mikala Egeblad, Nicholas K. Tonks. PTP1B inhibitors protect against acute lung injury and regulate CXCR4 signaling in neutrophils. JCI Insight, 2022; 7 (14) DOI: 10.1172/jci.insight.158199

Cite This Page:

Cold Spring Harbor Laboratory. "Disarming the immune system's lethal lung response." ScienceDaily. ScienceDaily, 23 September 2022. <www.sciencedaily.com/releases/2022/09/220923165300.htm>.
Cold Spring Harbor Laboratory. (2022, September 23). Disarming the immune system's lethal lung response. ScienceDaily. Retrieved February 21, 2024 from www.sciencedaily.com/releases/2022/09/220923165300.htm
Cold Spring Harbor Laboratory. "Disarming the immune system's lethal lung response." ScienceDaily. www.sciencedaily.com/releases/2022/09/220923165300.htm (accessed February 21, 2024).

Explore More
from ScienceDaily

RELATED STORIES